questions for the agm, page-27

Having attended the AGM this morning, I have come away somewhat disappointed. If Quintiles proves to give us double the margins of a traditional pharma, it wasn't managements first choice. In fact, it was their third choice having failed twice to get a deal with a big pharma. And it seems that dealing with Europe Common Market, you still have to deal with all the uncommon regulations of the different nation states so that Vitro gro will not be available across the ECM for years. And the "few hundred thousand in revenue for calendar 2012" leaves me thinking that this will be a long time before we make our fortunes in this stock. I think this will work out well but patient holders will have to remain patient.